Literature DB >> 26840145

Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.

Takahiro Hasegawa, Hajime Uno, Lee-Jen Wei.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26840145     DOI： 10.1056/NEJMc1514790

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2019-10-24       Impact factor: 44.544

2.  Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.

Authors:  Valsamo Anagnostou; Mark Yarchoan; Aaron R Hansen; Hao Wang; Franco Verde; Elad Sharon; Deborah Collyar; Laura Q M Chow; Patrick M Forde
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

3.  Moving beyond the Cox proportional hazards model in survival data analysis: a cervical cancer study.

Authors:  Lixian Li; Zijing Yang; Yawen Hou; Zheng Chen
Journal:  BMJ Open       Date:  2020-07-19       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.